The IDIAP Jordi Gol
Who we are
Organization
Quality Certification
Strategic plan
Annual reports
HRS4R
Transparency
Research
Territorial Support Units (USR)
Research Areas
Publications
Projects
CEIm
CEIM presentation
How to Submit the Documentation to the CEIM
Rates of The CEI
CEI meeting calendar
Regulations and links of interest CEI
Services and Platforms
AGICAP
Grants to Finance Research
Clinical Trial Monitoring
Platforms Questionnaires
Sidiap Database
Real World Lab
Tools-Help
Scientific Tools
Management Tools
IDIAP Management Tools
Innovation
News
Link GIR
Acces GIR
Login
Català
Castellano
English
The IDIAP Jordi Gol
Who we are
Organization
Quality Certification
Strategic plan
Annual reports
HRS4R
Transparency
Research
Territorial Support Units (USR)
Research Areas
Publications
Projects
CEIm
CEIM presentation
How to Submit the Documentation to the CEIM
Rates of The CEI
CEI meeting calendar
Regulations and links of interest CEI
Services and Platforms
AGICAP
Grants to Finance Research
Clinical Trial Monitoring
Platforms Questionnaires
Sidiap Database
Real World Lab
Tools-Help
Scientific Tools
Management Tools
IDIAP Management Tools
Innovation
News
Link GIR
Search
Most popular
COL·LABORA
Menu
English
Català
Español
Home
Àrees Recerca
CARDIOVASCULAR
GRECAP
GRECAP
Grup de recerca cadiovascular en atencio primaria (GRECAP)
Group leader
Miguel Angel Muñoz Pérez
mamunoz.bcn.ics@gencat.cat
Presentation
Team
Publications
Projects
News
Presentation
Team
Publications
Projects
News
Projects
Group projects
Reproductibilitat ecogràfica dels criteris de voltatge d’HVE i de les alteracions del segment ST-T
Principal investigators:
Ernest Vinyoles Bargalló
Code:
4R08/008
Start year:
2008
Funders:
ICS - Institut Català de la Salut
Epidemiology of Heart Failure in Catalonia: a cohort study
Principal investigators:
Miguel Angel Muñoz Pérez
Code:
4R15/076
Start year:
2015
Funders:
Novartis Pharma AG
An International Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Outpatients in Early Stages of COVID-19
Principal investigators:
Ernest Vinyoles Bargalló
Code:
5A21/007
Start year:
2021
AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2/3, DOUBLE-BLIND, 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332/RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID-19 WHO ARE AT LOW RISK OF PROGRESSING TO SEVERE ILLNESS
Principal investigators:
Ernest Vinyoles Bargalló
Code:
5A21/021
Start year:
2021
A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, DOUBLE DUMMY, PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF07321332/RITONAVIR IN PREVENTING SYMPTOMATIC SARS-COV-2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF INDIVIDUALS WITH SARS-COV-2 INFECTION
Principal investigators:
Ernest Vinyoles Bargalló
Code:
5A21/023
Start year:
2021
1
2
3
4
Següent
Board of Trustees
Collaborators
Accreditations